Shire PLC (NASDAQ:SHPG) – Equities research analysts at SunTrust Banks raised their FY2017 earnings estimates for shares of Shire PLC in a research note issued on Monday. SunTrust Banks analyst J. Boris now forecasts that the biopharmaceutical company will post earnings of $15.04 per share for the year, up from their previous estimate of $14.90. SunTrust Banks also issued estimates for Shire PLC’s Q4 2017 earnings at $4.08 EPS, FY2018 earnings at $16.37 EPS, FY2019 earnings at $20.26 EPS, FY2020 earnings at $23.86 EPS and FY2021 earnings at $27.25 EPS.

SHPG has been the subject of several other reports. Piper Jaffray Companies set a $159.00 target price on Shire PLC and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Zacks Investment Research lowered Shire PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Sanford C. Bernstein lowered Shire PLC from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $209.22 to $161.09 in a research report on Thursday, May 25th. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, HSBC Holdings plc lowered Shire PLC from a “hold” rating to a “reduce” rating in a research report on Friday, May 19th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Shire PLC presently has an average rating of “Buy” and an average target price of $222.27.

ILLEGAL ACTIVITY WARNING: “Shire PLC (SHPG) to Post FY2017 Earnings of $15.04 Per Share, SunTrust Banks Forecasts” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/shire-plc-shpg-to-post-fy2017-earnings-of-15-04-per-share-suntrust-banks-forecasts.html.

Shares of Shire PLC (NASDAQ SHPG) opened at 153.87 on Thursday. The firm has a market capitalization of $45.83 billion, a PE ratio of 157.82 and a beta of 1.60. Shire PLC has a 52 week low of $153.43 and a 52 week high of $209.22. The company’s 50 day moving average price is $165.41 and its 200-day moving average price is $172.82.

Shire PLC (NASDAQ:SHPG) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.53 by $0.20. The company had revenue of $3.75 billion during the quarter. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The company’s revenue was up 54.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.38 EPS.

Institutional investors have recently added to or reduced their stakes in the stock. Freestone Capital Holdings LLC increased its position in Shire PLC by 25.6% in the second quarter. Freestone Capital Holdings LLC now owns 5,092 shares of the biopharmaceutical company’s stock worth $842,000 after buying an additional 1,039 shares during the period. Northern Capital Management LLC increased its position in Shire PLC by 8.9% in the second quarter. Northern Capital Management LLC now owns 15,530 shares of the biopharmaceutical company’s stock worth $2,567,000 after buying an additional 1,275 shares during the period. Synovus Financial Corp increased its position in Shire PLC by 0.4% in the second quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 11 shares during the period. Oppenheimer Asset Management Inc. increased its position in Shire PLC by 63.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock worth $2,941,000 after buying an additional 6,917 shares during the period. Finally, Sequoia Financial Advisors LLC increased its position in Shire PLC by 4.8% in the second quarter. Sequoia Financial Advisors LLC now owns 1,412 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 65 shares during the period. Institutional investors and hedge funds own 21.04% of the company’s stock.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Earnings History and Estimates for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.